Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 21,893 shares, an increase of 184.6% from the April 30th total of 7,692 shares. Based on an average trading volume of 13,051 shares, the days-to-cover ratio is presently 1.7 days.
Relief Therapeutics Trading Up 1.3%
Relief Therapeutics stock opened at $0.48 on Friday. Relief Therapeutics has a one year low of $0.33 and a one year high of $4.88. The stock has a fifty day moving average of $0.47 and a 200 day moving average of $1.55.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Recommended Stories
- Five stocks we like better than Relief Therapeutics
- MongoDB’s AI Advantage Is Starting to Show Up in Results
- MarketBeat Week in Review – 05/25 – 05/29
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
